17:54 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro, cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds that...
19:20 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) or Tafinlar dabrafenib/Mekinist trametinib from...
18:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that once-daily 200 mg oral bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab...
15:16 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through the...
14:05 , Jun 7, 2018 |  BC Extra  |  Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through the...
19:09 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Astellas' AML candidate gilteritinib

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:00 , May 29, 2018 |  BC Extra  |  Company News

FDA reviewing Astellas' AML candidate

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:02 , May 25, 2018 |  BC Week In Review  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...
23:05 , May 22, 2018 |  BC Extra  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company Tuesday, including a restructuring of R&D and Japan operations. The pharma anticipates...
19:12 , May 18, 2018 |  BC Week In Review  |  Clinical News

Ipsen's Cabometyx MAA approved, Exelixis takes home $50M

Ipsen Group (Euronext:IPN; Pink:IPSEY) said the European Commission approved an MAA for Cabometyx cabozantinib to treat first-line renal cell carcinoma, triggering a $50 million milestone payment to partner Exelixis Inc. (NASDAQ:EXEL). Cabometyx will now be...